Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).

Angendohr C, Weigel C, Kunstein A, Joerdens M, Goetze T, Al-Batran SE, Zäpf B, Gonzalez-Carmona M, Sahin C, Berres ML, Foerster F, Ben Khaled N, Koch C, Kandulski A, Wege H, Trebicka J, Jochheim LS, Dill MT, Springfeld C, Daum S, Treese C, Ehmer U, Luedde T, Bode J, Roderburg C

DOI: 10.1080/14796694.2026.2748246

На странице источника доступны аннотация, полный текст или сведения о том, где его прочитать.